Routine versus selective antifungal administration for control of fungal infections in patients with cancer

Cochrane Database of Systematic Reviews

Volumn 2002, Issue 2, 2002, Pages

  Gøtzsche, Peter C ^a   Johansen, Helle Krogh ^a  

^a Nordic Cochrane Centre   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGY; MYCOSIS; NEOPLASM; NEUTROPENIA; OPPORTUNISTIC INFECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTIFUNGAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; NEOPLASMS; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; RANDOMIZED CONTROLLED TRIALS;

EID: 0036053594     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000026     Document Type: Review

References (97)

1. Acuna G, Winston DJ, Young LS. Ketoconazole prophylaxis of fungal infections in the granulocytopenic patient: a double-blind, randomized controlled trial. Program and Abstracts of 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, 1981. 1981:abstract 852.
2. Benhamou E, Hartmann O, Nogues C, Maraninchi D, Valteau D, Lemerle J. Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. Bone Marrow Transplant 1991;7(2):127-31.
3. Hartmann O, Benhamou E, Maraninchi D, Valteau D, Brugières L, Kalifa C, et al.Results of a randomized double-blind placebo controlled trial with ketoconazole in the prevention of fungal infection in children treated with high dose chemotherapy and BMT [abstract]. Bone Marrow Transplant 1990;5 Suppl 2:19.
4. Brincker H. Prophylactic treatment with miconazole in patients highly predisposed to fungal infection. A placebo-controlled double-blind study. Acta Medica Scandinavica 1978;204(1-2):123-8.
5. Brincker H. Prevention of mycosis in granulocytopenic patients with prophylactic ketoconazole treatment. Mykosen 1983;26(5):242-7.
6. Caselli D, Arico M, Michelone G, Cavanna C, Nespoli L, Burgio GR. Antifungal chemoprophylaxis in cancer children: a prospective randomized controlled study. Microbiologica 1990;13:347-51.
7. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. The American Journal of Medicine 1989;86:668-72.
8. Estey E, Maksymiuk A, Smith T, Fainstein V, Keating M, McCredie KB. Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. Archives of Internal Medicine 1984;144(8):1562-8.
9. Fukuda M, Hirashima K, Kurane R, Abe T, Sampi K, Tominaga K. [Empiric therapy with fluconazole in granulocytopenic patients with carcinoma or leukemia][Japanese]. The Japanese Journal of Antibiotics 1994;47(8):1065-70.
10. Goldstone AH, O'Driscoll A. Early AmBisome in febrile neutropenia in patients with haematological disorders. Bone Marrow Transplant 1994;14 Suppl 5:S15-7.
11. Chandrasekar PH, Gatny CM. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team. Chemotherapy 1994;40(2):136-43.
12. Chandrasekar PH, Gatny CM. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team. The Journal of Antimicrobial Chemotherapy 1994;33(2):309-18.
13. Goodman JL, Greenfield R, Buell D. Prophylactic fluconazole and marrow transplantation [correspondence]. The New England Journal of Medicine 1992;327:645.
14. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. The New England Journal of Medicine 1992;326(13):845-51.
15. Hansen RM, Reinerio N, Sohnle PG, Abrams RA, Ritch PS, Libnoch JA. Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study. Archives of Internal Medicine 1987;147(4):710-2.
16. Hughes WT, Bartley DL, Patterson GG, Tufenkeji H. Ketoconazole and candidiasis: a controlled study. The Journal of Infectious Diseases 1983;147(6):1060-3.
17. Kaptan K, Ural AU, Cetin T, Avcu F, Beyan C, Yalcin A. Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia. Journal of Infection and Chemotherapy 2003;9:40-5.
18. Kelsey SM, Goldman JM, McCann S. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999;23(2):163-8.
19. Kern W, Behre G, Büchner T, Hiddemann W. Failure of fluconazole prophylaxis to reduce mortality during treatment for refractory acute myeloid leukemia: a phase III multicenter study [abstract]. Annals of Hematology 1996;73 suppl 2:A10.
20. Kern W, Behre G, Kerkhoff A, Grote-Metke A, Eimermacher H, Kubica U. Failure of fluconazole prophylaxis to reduce mortality during treatment for refractory acute myleoid leukemia: results of a phase III multicenter study. Annals of Hematology 1997;74 Suppl 1:A52, abstract 207.
21. Kern W, Behre G, Rudolf T. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 1998;83:291-301.
22. Menichetti F, Del Favero A, Martino P. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America 1999;28(2):250-5.
23. del Favero A, Menichetti F, Micozzi A, Bucaneve G, de Beule K, Martino P. Antifungal prophylaxis in neutropenic pts (<1000/mmc) with haematological malignancy: a double-blind trial to compare itraconazole oral solution (IOS) with placebo (PLA). 37th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC); 28 Sept-1 Oct 1997; Toronto 1997;abstract:LM-84.
24. Nucci M, Biasoli I, Akiti T, Silveira F, Solza C, Barreiros G. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America 2000;30(2):300-5.
25. Nucci M, Biasoli I, Akiti T, Silveira F, Solza C, Barreiros G, et al.A double-blind, randomized placebo-controlled trial of itraconazole capsules for antifungal prophylaxis in neutropenic patients. The Tenth International Symposium on Infections in the Immunocompromised Host. Davos, Switzerland, 21-24 June 1998. International Immunocompromised Host Society, 1998:Abstract 104.
26. Nucci M, Biasoli I, Solza C, Silveira F, Akiti T, Derossi A. Itraconazole capsules versus placebo in the prophylaxis of fungal infections in neutropenic cancer patients: a double-blind, randomized study. Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), 38th Meeting, San Diego, Sept 24-27 1998. 1998:Abstract J-102 (p. 480).
27. Palmblad J, Lönnqvist B, Carlsson B, Grimfors G, Järnmark M, Lerner R. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: more bacteraemias. Journal of Internal Medicine 1992;231(4):363-70.
28. Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, et al.A randomized phase III trial of low dose liposomal amphotericin B (L-AmB) as prophylaxis of invasive fungal infections (IFI) in neutropenic patients (pts). Blood. Proceedings of the 47th Annual Meeting of the American Society of Hematology; 10-13 December, 2005; Atlanta, Georgia, 2005; Vol. 106, issue 11:Abstract No. 82.
29. Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, et al.Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Annals of Oncology 2006;17(8):1306-12.
30. Penack OP, Reinwald M, Schmidt-Hieber M, Schwartz S, Thiel E, Blau IW. Low dose liposomal amphotericin B (L-AMB) as prophylaxis of invasive fungal infections in patients (pts) with prolonged neutropenia: preliminary results of a randomized phase III trial. 10th Congress of the European Hematology Association 2005;abstract:0376.
31. Perfect JR, Klotman ME, Gilbert CC. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. The Journal of Infectious Diseases 1992;165(5):891-7.
32. Pizzo PA, Robichau KJ, Simon R. Empiric antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Proceedings of the American Association of Cancer Research. 1980:Abstract C-115 (p. 348).
33. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. The American Journal of Medicine 1982;72(1):101-11.
34. Riley D, Beatty P, Pavia A, Evans TG. Prophylactic use of low-dose amphotericin B (AMB) in bone marrow transplant (BMT) patients. 32nd Interscience Conference of Antimicrobial Agents and Chemotherapy. American Society for Microbiology, 1992. 1992:abstract 620.
35. Riley DK, Pavia AT, Beatty PG. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. The American Journal of Medicine 1994;97(6):509-14.
36. Laverdiere M, Rotstein C, Bow EJ, Carr D, Moghaddam N, Ioannou S and the Canadian Fluconazole Study Group. The impact of fluconazole (F) prophylaxis on fungal colonization and subsequent infection in cancer neutropenic patients. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC); 28 Sept-1 Oct 1997; Toronto 1997;abstract:LM-85.
37. Laverdiere M, Rotstein C, Bow EJ, Roberts RS, Ioannou S, Carr D et al and the Canadian Fluconazole Study Group. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. Journal of Antimicrobial Chemotherapy 2000;46:1001-8.
38. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America 1999;28(2):331-40.
39. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. The Journal of Infectious Diseases 1995;172(4):1035-41.
40. Siegel M, Murphy M, Counts GW, Meyers JD. Prophylactic ketoconazole for the prevention of fungal infection in bone marrow transplant patients. 23rd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology, 1982. 1982:abstract 166.
41. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers MED. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055-61.
42. Slavin M, Bowden R, Osborne B, Adams R, Levenstein M, Feldman A. Fluconazole prophylaxis in marrow transplant recipients: a randomized placebo controlled double blind study. 32nd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology, 1992. 1992:abstract 623.
43. Slavin MA, Osborne B, Adams R, Levenstein M, Schoch HG, Feldman AR. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. The Journal of Infectious Diseases 1995;171(6):1545-52.
44. Upton A, McCune JS, Kirby KA, Leisenring W, McDonald G, Batchelder A, et al.Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 2007;13(7):760-4.
45. Suda T, Omine M, Tsuchiya J, Maekawa T, Muto Y, Mizoguchi H. [A co-operative study on prophylaxis of fungal infection in patients with hematological diseases: prophylactic effect of oral administration of amphotericin B][Japanese]. [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology 1980;21(2):195-9.
46. Tollemar J, Hockerstedt K, Ericzon BG, Sundberg B, Ringden O. Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies. Transplantation Proceedings 1994;26(3):1833.
47. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Sparrelid E. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplantation Proceedings 1993;25(1 Pt 2):1495-7.
48. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplantation 1993;12(6):577-82.
49. Tollemar J, Ringdén O. Double-blind randomized trials with AmBisome (TM) as prophylaxis in bone marrow and liver transplant patients. Bone Marrow Transplantation 1993;12(suppl 4):S151-2.
50. Vreugdenhil G, Van Dijke BJ, Donnelly JP, Novakova IRO, Raemaekers JMM, Hoogkamp-Korstanje MAA. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leukemia & Lymphoma 1993;11(5-6):353-8.
51. Wingard JR, Vaughan WP, Braine HG, Merz WG, Saral R. Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. The American Journal of Medicine 1987;83(6):1103-10.
52. Kelsey SM, Goldman JM, McCann S. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplantation 1999;23(2):163-8.
53. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Annals of Internal Medicine 1993;118(7):495-503.
54. Yamac K, Senol E, Haznedar R. Prophylactic use of fluconazole in neutropenic cancer patients. Postgraduate Medical Journal 1995;71(835):284-6.
55. Benhamou E, Hartmann O, Nogues C, Maraninchi D, Valteau D, Lemerle J. Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. Bone Marrow Transplantation 1991;7(2):127-31.
56. Bodey GP, Samonis G, Rolston K. Prophylaxis of candidiasis in cancer patients. Seminars in oncology 1990;7 Suppl 6:24-8.
57. Brincker H. Personal communication; unpublished study on fluconazole 1990.
58. Ezdinli EZ, O'Sullivan DD, Wasser LP, Kim U, Stutzman L. Oral amphotericin for candidiasis in patients with hematologic neoplasms. An autopsy study. JAMA 1979;242(3):258-60.
59. Hiddemann W, Essink ME, Fegeler W, Zuhlsdorf M, Sauerland C, Buchner T. Antifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia. Cancer 1991;68(1):9-14.
60. Prentice AG, Bradford GR. Prophylaxis of fungal infections with itraconazole during remission-induction therapy. Mycoses 1989; Vol. 32 Suppl 1:96-102 (describes an unpublished study).
61. Reed E, Rasmussen J, Robertson P, Armitage J, Bierman P, Vose J. Interim analysis of fluconazole (flu), intermittent amphotericin (ampho) and no treatment (ntx) for prophylaxis of fungal disease in bone marrow transplant (bmt) and acute leukemia (al) patients (pts). Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1993;12:465, abstract 1622.
62. Samonis G, Rolston K, Karl C, Miller P, Bodey G. Prophylaxis of oropharyngeal candidiasis with fluconazole. Reviews of Infectious Diseases 1990;12 suppl 3:S369-73.
63. Schaison G, Baruchel A, Arlet G. Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children. British Journal of Haematology 1990;76 Suppl 2:24-6.
64. Schiel X, Link H, Maschmeyer G, Cornely OA, Buchheidt D, Wilhelm M, et al.A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. Infection 2006;34(3):118-26.
65. Siegel M, Murphy M, Counts GW, Meyers JD. Prophylactic ketoconazole for the prevention of fungal infection in bone marrow transplant patients. 23rd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology, 1982. 1982:abstract 166.
66. Vehreschild JJ, Bohme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, et al.A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). Journal of Infection 2007;55(5):445-9.
67. Wang CY, Wu BY, Guo KY. A controlled clinical trial of itraconazole for prevention of fungal infections secondary to chemotherapy. Di Yi Jun Yi Da Xue Xue Bao [Academic Journal of the First Medical College of PLA] 2003;23(4):389-90.
68. Cornely OA, Böhme A, Vehreschild JJ, Buchheidt D, Arenz D, Harnischmacher U, et al.Evaluating voriconazole (VCZ) as primary antifungal prophylaxis during induction chemotherapy for acute myelogenous leukemia (AML). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sept 27-30; San Francisco. 2006: abstract M-884.
69. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001;357(9270):1766-7.
70. Berlin JA, Begg CB, Louis TA. An assessment of publication bias using a sample of published clinical trials. Journal of the American Statistical Association 1989;84:381-92.
71. Buyse M. Interim analyses, stopping rules and data monitoring in clinical trials in Europe. Statistics in Medicine 1993;2:509-20.
72. Chalmers I. Underreporting research is scientific misconduct. JAMA 1990;263:1405-8.
73. Chan AW, Hrobjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291(20):2457-65.
74. Due AK, Johansen HK, Gøtzsche PC. Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents. BioMed Central Medical Research Methodology 2006;6:40.
75. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Causes of initial remission induction failure in acute myelogenous leukemia. Blood 1982;60:309-15.
76. Gøtzsche PC. Multiple publication of reports of drug trials. European Journal of Clinical Pharmacology 1989;36(5):429-32.
77. Huston P, Moher D. Pharmaceutical company trials and the integrity of medical research (letter). Lancet 1996;347:1628.
78. Inagaki J, Rodriguez V, Bodey G. Causes of death in cancer patients. Cancer 1974;33:568-73.
79. Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-9.
80. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD000969].
81. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD000239].
82. Johansen HK, Gøtzsche PC. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD002033].
83. Jørgensen KJ, Gøtzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004707].
84. Meyers JD. Fungal infections in bone marrow transplant patients. Seminars in Oncology 1990;17:10-3.
85. Pocock SJ. Size of cancer clinical trials and stopping rules. British Journal of Cancer 1978;38:757-66.
86. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias, dimension of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
87. Simes RJ. Publication bias: the case for an international registry of clinical trials. Journal of Clinical Oncology 1986;4:529-41.
88. Stein RS, Greer JP, Ferrin W, Lenox R, Baer MR, Flexner JM. Clinical experience with amphotericin B in acute myelogenous leukemia. Southern Medical Journal 1986;79(7):863-70.
89. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997;315:640-5.
90. Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay N, McGlave P. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991;8:177-84.
91. Walsh TJ. Role of surveillance cultures in prevention and treatment of fungal infections. Journal of National Cancer Institute Monographs 1990;9:43-5.
92. Walsh TJ, Lee J, Lecciones J, Rubin M, Butler K, Francis P. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Reviews of Infectious Diseases 1991;13(3):496-503.
93. Working Party of the British Society for Antimicrobial Chemotherapy. Antifungal drug susceptibility testing. The Journal of Antimicrobial Chemotherapy 1995;36:899-909.
94. Gøtzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997;314:1238-44.
95. Gøtzsche PC, Johansen HK. Antifungal prophylactic or empiric therapy versus placebo or no treatment in cancer patients with neutropenia. Cochrane Database of Systematic Reviews 1997, Issue 2.
96. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review). Cochrane Database of Systematic Reviews 2000, Issue 2.. [DOI: 10.1002/14651858.CD000026].
97. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD000026].